Repligen (NASDAQ:RGEN) Issues Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Repligen (NASDAQ:RGEN) posted its earnings results on Tuesday. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.09, FiscalAI reports. The firm had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The company’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.26 earnings per share. Repligen updated its FY 2026 guidance to 2.030-2.090 EPS.

Here are the key takeaways from Repligen’s conference call:

• Strong Q2 results and raised guidance: Revenue reached $204 million, up 12% reported and 13% organically, while adjusted EPS rose 46% to $0.54. Repligen raised its full-year organic growth outlook to 10.5%–13.5% and adjusted EPS guidance to $2.03–$2.09.
• Broad-based franchise momentum: Proteins grew 50%, Analytics increased more than 30%, and Chromatography delivered low-double-digit growth. Emerging biotech grew at a high-teens rate for the fifth consecutive quarter, suggesting improving customer funding and demand.
• Margin expansion continued: Adjusted operating margin expanded 460 basis points to 16.7%, supported by volume leverage, pricing, product mix, and manufacturing efficiencies. The company raised full-year operating margin guidance to 15.7%–16% while remaining on track for its 30% adjusted EBITDA margin target by 2030.
• BioLife acquisition expected to add growth and earnings: Management said the planned acquisition will accelerate Repligen’s cell-therapy strategy and add at least $20 million of synergies and $0.05 of adjusted EPS accretion in year one, rising to at least $30 million and $0.25 in year two. The transaction is not included in current 2026 guidance and remains subject to customary approvals.
• Filtration remains a near-term weak spot: Filtration revenue grew only slightly as gene-therapy exposure, customer inventory reductions, site-readiness delays, and the Polymem divestiture weighed on results. Management expects some of these pressures to persist into Q3, although ATF order momentum and normalization are anticipated in Q4 and 2027.

Repligen Price Performance

Shares of RGEN opened at $152.77 on Tuesday. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. The company’s fifty day simple moving average is $132.21 and its 200 day simple moving average is $132.05. Repligen has a 1-year low of $100.99 and a 1-year high of $175.77. The company has a market cap of $8.62 billion, a price-to-earnings ratio of 167.36, a PEG ratio of 2.54 and a beta of 1.06.

Analyst Ratings Changes

Several research firms have recently weighed in on RGEN. Jefferies Financial Group reiterated a “hold” rating and issued a $142.00 price target on shares of Repligen in a report on Tuesday, May 5th. Roth Capital began coverage on Repligen in a report on Friday, April 17th. They issued a “buy” rating and a $160.00 price target on the stock. Wolfe Research assumed coverage on Repligen in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price objective for the company. Canaccord Genuity Group decreased their price objective on Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a report on Monday, April 20th. Finally, Weiss Ratings raised Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, July 14th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $165.36.

Key Stories Impacting Repligen

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Repligen delivered Q2 revenue of $204.1 million, up 11.9% year over year and above the $201.6 million consensus estimate. Organic revenue growth was 13%, reflecting continued order momentum and sequential improvement. Repligen Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Adjusted diluted EPS was $0.54, exceeding the $0.45 analyst consensus and rising from $0.37 a year earlier. Adjusted operating income increased 55% to $34 million, while adjusted operating margin expanded to 16.7% from 12.0%. Repligen Quarterly Earnings Results
• Positive Sentiment: Management raised full-year 2026 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS guidance to $2.03-$2.09, above the approximately $2.00 consensus EPS forecast. Total reported revenue is expected to reach $813 million-$835 million. Repligen Raises Full-Year Guidance
• Positive Sentiment: Repligen announced a definitive agreement to acquire BioLife Solutions, a deal management expects to strengthen its cell-therapy position and contribute to revenue growth, margins and adjusted EPS. The company ended June with $810 million in cash, cash equivalents and marketable securities, supporting financial flexibility.
• Neutral Sentiment: Investors must distinguish the adjusted results from GAAP results: GAAP diluted EPS fell to $0.09 from $0.26, while net income declined to $5.0 million from $14.9 million. The difference was driven largely by acquisition, restructuring, transformation, amortization and other items.
• Negative Sentiment: GAAP net margin dropped to 2.5% from 8.2%, and GAAP operating margin edged down to 6.8% from 7.6%. These figures may temper enthusiasm, particularly given RGEN’s elevated valuation, including a reported price-to-earnings ratio above 145.
• Negative Sentiment: The BioLife Solutions transaction remains subject to completion and integration risks, while recent insider activity cited in the coverage showed two sales and no purchases over the past six months.

Insider Buying and Selling

In other news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at $2,807,055. This trade represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Repligen

A number of institutional investors and hedge funds have recently modified their holdings of the company. United Capital Financial Advisors LLC acquired a new stake in Repligen in the 3rd quarter valued at about $368,387,000. Opti Capital Management LP bought a new stake in Repligen in the fourth quarter valued at approximately $2,399,209,000. Price T Rowe Associates Inc. MD raised its stake in Repligen by 31.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after buying an additional 1,091,683 shares during the period. RTW Investments LP acquired a new stake in shares of Repligen in the fourth quarter valued at approximately $174,347,000. Finally, Balyasny Asset Management L.P. boosted its stake in shares of Repligen by 390.6% during the 3rd quarter. Balyasny Asset Management L.P. now owns 767,239 shares of the biotechnology company’s stock worth $102,557,000 after acquiring an additional 610,837 shares during the period. 97.64% of the stock is owned by institutional investors.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.